Cancer Immunology, Immunotherapy

, Volume 61, Issue 1, pp 137–143 | Cite as

Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25–27, 2011, Mainz, Germany

  • Kathleen Hobohm
  • Torsten Seppmann
  • Cedrik M. Britten
  • Holger HoffEmail author
Meeting report

CIMT 2011 was the ninth annual meeting organized by the Association for Cancer Immunotherapy (CIMT). More than 500 international participants met in Mainz, Germany, to discuss the latest topics in cancer immunotherapy. A total of 176 posters were presented by young scientists, and several of them were selected for short talk sessions. Three industry satellite symposia provided insights into new developments in state-of-the-art technologies to enhance cancer immunotherapy. The major topics of CIMT 2011 were trends in cellular therapies, therapeutic vaccination, improving immunity, immunoguiding, regulatory research and optimizing early clinical trials. This meeting report summarizes selected presentations to give an overview over the fields discussed during the meeting.

Immunotherapy: recent approvals and promising clinical trials shape the new field of immuno-oncology

Exactly 2 months prior to CIMT 2011, the FDA approved ipilimumab (anti-CTLA-4) as a new treatment for late-stage...


Ipilimumab Cancer Immunotherapy Cancer Vaccine Fred Hutchinson Cancer Research Immunogenic Cell Death 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest

CMB is executive director of CIMT and co-organizer of CIMT 2011. All authors declare no conflict of interest.

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Kathleen Hobohm
    • 1
  • Torsten Seppmann
    • 1
  • Cedrik M. Britten
    • 1
    • 2
  • Holger Hoff
    • 3
    • 4
    Email author
  1. 1.Department of Internal Medicine III, Translational and Experimental OncologyUniversity Medical CenterMainzGermany
  2. 2.Ribological GmbHMainzGermany
  3. 3.TRON Translational Oncology at University Medical Center MainzMainzGermany
  4. 4.UniCell GmbHMainzGermany

Personalised recommendations